Total number of shares and voting rights in Zealand Pharma at June 30, 2021
Zealand Pharma A/S announced the total number of shares and voting rights on June 30, 2021, following an increase in share capital due to employee warrants exercises. As of this date, Zealand maintains 43,541,838 shares and 43,541,838 voting rights, reflecting no changes in share capital since the previous reporting. Zealand Pharma focuses on peptide-based medicines, having two products on the market and several in clinical development. The company continues to engage in collaborations to expand the reach of its medicines.
- Total shares and voting rights remain at 43,541,838 as of June 30, 2021.
- Company has a strong pipeline with two drugs approved and several in development.
- Partnerships with Boehringer Ingelheim and Alexion Pharmaceuticals may enhance product reach.
- None.
Company announcement – No. 44/ 2021
Total number of shares and voting rights in Zealand Pharma at June 30, 2021
Copenhagen, DK and Boston, MA, June 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 37/2021 from June 10, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including June 30, 2021.
Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| June 30, 2021 | 43,541,838 | 43,541,838 | 43,541,838 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and has received FDA approval for Zegalogue, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Claudia Styslinger |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What is the total number of shares for ZEAL as of June 30, 2021?
How many voting rights does ZEAL have as of June 30, 2021?
What was announced in Zealand Pharma's company announcement No. 44?
What does Zealand Pharma specialize in?
